

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	340514	BLACKMORES LUTEIN-VISION ADVANCED
ARTG entry for	Medicine Listed	
Sponsor	Blackmores Ltd	
Postal Address	PO Box 1725, W Australia	ARRIEWOOD, NSW, 2102
ARTG Start Date	30/07/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. BLACKMORES LUTEIN-VISION ADVANCED

Product Type	Single Medicine Product	Effective Date	30/07/2020
Permitted Indication	ons		
Antioxidant/Reduce	free radicals formed in the body		
Helps reduce/decre	ase free radical damage to body cells		
Maintain/support he	althy eye function		
Maintain/support ey	re health		
Helps maintain/supp	port eye macula health		
Helps maintain/supp	port eye retina health		
Maintain/support he	althy eyesight/vision		
Indication Require	ments		
Product presentation	on must not imply or refer to vision corre	ction, faults or serious eye disease e.g. n	nacular degeneration.
Standard Indicatio	ns		
No Standard Indicat	tions included on Record		
Specific Indication	IS		
No Specific Indication	ons included on Record		
Warnings			
This medicine conta exceeded.	ains selenium which is toxic in high dose	s. A daily dose of 150 micrograms for ad	ults of selenium from dietary supplements should not l
Additional Product	t information		
Pack Size/Poison i	information		
		Poison Schedule	
Pack Size		Poison Schedule	
Page 1 of 2			Produced at 03.02.2022 at 04:07:07 AEDT
	ARTG Certificate document.	and the former the second second	and the design of the distribution of the second
i ne onus is on t	ne reader to verify the current accu	racy of the information on the docur	ment subsequent to the date shown.

Visit www.tga.gov.au for contact information



Australian Government

Department of Health Therapeutic Goods Administration

omponents		
1. Formulation 1		
Dosage Form	Capsule, soft	
Route of Administration	Oral	
Visual Identification		
Active Ingredients		
concentrated fish Omega-3 triglycerides		850 mg
Equivalent: docosahexaenoic acid		176 mg
Equivalent: eicosapentaenoic acid		352 mg
selenomethionine		124.19 microgram
Equivalent: selenium		50 microgram
zeaxanthin		.9996 mg
Other Ingredients (Excipie	ents)	
ascorbyl palmitate		
colloidal anhydrous silica	1	
Gelatin		
glycerol		
hydrogenated vegetable o	bil	
iron oxide black		
iron oxide red		
lecithin		
medium chain triglyceride	es	
mixed (low-alpha type) too	copherols concentrate	
Olive Oil		
purified water		
Safflower Oil		
Soya Oil		
vanillin		
yellow beeswax		

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information

This is not an ARTG Certificate document.